Yervoy

Chemical Nameipilimumab
Dosage FormInjection (intravenous; 5 mg/mL)
Drug ClassCytotoxic T-lymphocyte antigen 4 blocking antibodies
SystemMultiple
CompanyBristol Myers Squibb
Approval Year2011

Indication

  • For the treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older.
  • For the treatment of adult patients with unresectable or metastatic melanoma, in combination with nivolumab.
  • For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
  • For the treatment of patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab.
  • For the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab.
  • For the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, in combination with nivolumab.
  • For the treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab.
  • For the treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy.
  • For the treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab.
Last updated on 1/11/2023

More on this drug: Clinical Trials

Document TitleYearSource
Yervoy (ipilimumab) Prescribing Information.2022Bristol-Myers Squibb Company, Princeton, NJ
Document TitleYearSource
Severe immune‑related adverse events of immune checkpoint inhibitors for advanced non‑small cell lung cancer: a network meta‑analysis of randomized clinical trials.2022Cancer Immunology, Immunotherapy
Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis.2022European Urology Open Science
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.2022ESMO Open
Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review. 2022BMJ Open Ophthalmology
The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with stage III/IV unresectable melanoma: a systematic review and meta‑analysis.2022Journal of Cancer Research and Therapeutics
Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%–49%: a network meta-analysis.2022Thoracic Cancer
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis.2021Therapeutic Advances in Urology
Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis.2021Cancer Cell International
The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis.2021Translational Lung Cancer Research
Comparative efficacy of treatments for brain metastases from non–small cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis.2021World Neurosurgery
Immune-related adverse events associated with immune checkpoint inhibitors for advanced non-small cell lung cancer: a network meta-analysis of randomized clinical trials.2021Frontiers in Pharmacology
Immune checkpoint inhibitor with or without radiotherapy in melanoma patients with brain metastases: a systematic review and meta-analysis.2021Korean Journal of Radiology
Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.2021BMC Cancer
Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: a systematic review and network meta-analysis.2021Thoracic Cancer
Chemotherapy in focus: a meta-analysis confronts immunotherapy in the treatment of advanced melanoma.2021Critical Reviews in Oncology/Hematology
A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma.2021European Urology
Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: systematic review and meta-analysis.2021PLoS One
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.2021Therapeutic Advances in Medical Oncology
Systematic review and meta‑analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti‑PD‑1 progression: a systematic review and meta‑analysis.2021Clinical and Translational Oncology
Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer.2021The Cochrane Database of Systematic Reviews
Economic evaluation of systemic treatments for advanced melanoma: a systematic review.2020Value in Health
The risk ratio of immune-related colitis, hepatitis, and pancreatitis in patients with solid tumors caused by PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.2020Frontiers in Oncology
Immune checkpoint inhibitors and immune-related adverse events in patients with advanced melanoma.2020JAMA Network Open
First-line treatments for advanced renal cell carcinoma with immune checkpoint inhibitors: systematic review, network meta-analysis and cost-effectiveness analysis.2020Therapeutic Advances in Medical Oncology
Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review.2020Therapeutic Advances in Medical Oncology
Targeted therapy for metastatic renal cell carcinoma.2020The Cochrane Database of Systematic Reviews
Immune checkpoint inhibitors in advanced acral melanoma: a systematic review.2020Frontiers in Oncology
Immunotherapy for metastatic renal cell carcinoma: a systematic review.2019Journal or Evidence-Based Medicine
Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: a Bayesian network analysis. 2019EBioMedicine
The differences in the safety and tolerability of immune checkpoint inhibitors as treatment for non–small cell lung cancer and melanoma: network meta-analysis and systematic review.2019Frontiers in Pharmacology
Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis.2018Journal of Immunology Research
Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review.2018Melanoma Management
Clinical and molecular characteristics associated with survival in advanced melanoma treated with checkpoint inhibitors.2018Journal of Oncology
Efficacy and safety of ipilimumab plus chemotherapy for advanced lung cancer: a systematic review and meta-analysis. 2018Journal of Cancer
Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis.2017Clinical, Cosmetic and Investigational Dermatology
Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review.2017Cancer Treatment Reviews
Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.2017Pharmacology and Therapeutics
Risk of treatment-related mortality in cancer patients treated with ipilimumab: a systematic review and meta-analysis.2017European Journal of Cancer
Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.2017Expert Review of Anticancer Therapy
Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.2017Clinical Oncology